SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-286274
Filing Date
2020-11-05
Accepted
2020-11-05 08:11:03
Documents
14
Period of Report
2020-11-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d30873d8k.htm   iXBRL 8-K 24281
2 EX-99.1 d30873dex991.htm EX-99.1 90193
6 GRAPHIC g30873g1105090158435.jpg GRAPHIC 4588
  Complete submission text file 0001193125-20-286274.txt   260681

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA clvs-20201105.xsd EX-101.SCH 3087
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE clvs-20201105_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clvs-20201105_pre.xml EX-101.PRE 11419
7 EXTRACTED XBRL INSTANCE DOCUMENT d30873d8k_htm.xml XML 3356
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

IRS No.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35347 | Film No.: 201288798
SIC: 2834 Pharmaceutical Preparations